Zhao Xu, Hao Jian, Chen Sinuan
Department of Traditional Chinese Medicine, Shenzhen Longgang Central Hospital, Shenzhen, Guangdong Province 518116, China.
Clinical Cancer Therapy Center, The Fourth Central Hospital of NanKai University, Hebei District, 300140 Tianjin, China.
Evid Based Complement Alternat Med. 2020 Mar 14;2020:6076572. doi: 10.1155/2020/6076572. eCollection 2020.
To investigate the potential therapy targets and pharmacological mechanism of traditional Chinese medicine (TCM) Xihuang pill in liver cancer based on network pharmacology.
Drug ingredients-target network was constructed based on the target sets of Xihuang pill and liver cancer. The overlapping genes between Xihuang pill targets and liver cancer-related molecular targets were investigated using comparative analysis. Moreover, the PPI network and module was constructed based on overlapping genes and hub nodes, respectively, followed by the pathway enrichment analysis.
A drug ingredients-target network was established with 1184 nodes and 11035 interactions. Moreover, a total of 106 overlapping genes were revealed between drug targets and liver cancer molecular targets. Furthermore, a PPI network and 4 modules were further investigated based on overlapping genes, respectively. These hub nodes such as VEGFA and EGFR were mainly enriched in GO functions including positive regulation of MAP kinase activity, activation of protein kinase activity, regulation of MAP kinase activity, and pathways like proteoglycans in cancer, bladder cancer, and estrogen signaling.
VEGFA and EGFR might be potential therapy targets of Xihuang pill in liver cancer. Furthermore, the effect of Xihuang pill on liver cancer might be realized by targeting VEGFA and EGFR in pathways like proteoglycans in cancer and estrogen signaling.
基于网络药理学探讨中药西黄丸在肝癌中的潜在治疗靶点及药理机制。
基于西黄丸和肝癌的靶点集构建药物成分-靶点网络。通过比较分析研究西黄丸靶点与肝癌相关分子靶点之间的重叠基因。此外，分别基于重叠基因和枢纽节点构建蛋白质-蛋白质相互作用（PPI）网络和模块，随后进行通路富集分析。
建立了一个包含1184个节点和11035个相互作用的药物成分-靶点网络。此外，在药物靶点与肝癌分子靶点之间共揭示了106个重叠基因。进一步基于重叠基因分别研究了一个PPI网络和4个模块。这些枢纽节点如血管内皮生长因子A（VEGFA）和表皮生长因子受体（EGFR）主要富集于包括丝裂原活化蛋白激酶（MAP）激酶活性的正调控、蛋白激酶活性的激活、MAP激酶活性的调节等GO功能，以及癌症中的蛋白聚糖、膀胱癌和雌激素信号等通路。
VEGFA和EGFR可能是西黄丸在肝癌中的潜在治疗靶点。此外，西黄丸对肝癌的作用可能是通过在癌症中的蛋白聚糖和雌激素信号等通路中靶向VEGFA和EGFR来实现的。
